ERBB2 and gastric cancer: The Trastuzumab for Gastric Cancer (ToGA) study demonstrated significantly improved overall survival (OS) with the addition of trastuzumab to chemotherapy in patients with previously untreated HER2-positive locally advanced/metastatic gastric/gastroesophageal junction cancer (GC/GEJC) [1].